Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2013 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Cash from Investing Activities of -$16.7 million for Q1 2026, down 259.65% year-over-year from $10.5 million in Q1 2025, and up 72.37% quarter-over-quarter from -$60.6 million in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$16.7 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 259.65% year-over-year to -$16.7 million; the TTM figure through Mar 2026 stood at -$97.5 million (up 24.78% YoY), while the FY2025 annual figure was -$70.3 million, up 43.7% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$16.7 million, up from -$60.6 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $15.2 million in Q1 2024, with the low at -$508.6 million in Q2 2023.
- The 5-year median for Cash from Investing Activities is -$16.7 million (2026), against an average of -$52.6 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities slumped 44899.56% in 2023, then soared 340.6% in 2024.
- Amphastar Pharmaceuticals' Cash from Investing Activities stood at -$229000.0 in 2022, then plunged by 44899.56% to -$103.0 million in 2023, then jumped by 65.38% to -$35.7 million in 2024, then sank by 69.77% to -$60.6 million in 2025, then soared by 72.37% to -$16.7 million in 2026.
- Business Quant data shows AMPH's Cash from Investing Activities at -$16.7 million in Q1 2026, -$60.6 million in Q4 2025, and -$19.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 945.33 Mn | 655.21 Mn | 93.47 Mn | 44.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 44.87 Mn |
| Jun 30, 2026 | 44.87 Mn |
| Mar 31, 2026 | -16.73 Mn |
| Mar 31, 2026 | -16.73 Mn |
| Dec 31, 2025 | -60.57 Mn |
| Dec 31, 2025 | -60.57 Mn |
| Sep 30, 2025 | -19.62 Mn |
| Sep 30, 2025 | -19.62 Mn |
| Jun 30, 2025 | -625,000.00 |
| Jun 30, 2025 | -625,000.00 |
| Mar 31, 2025 | 10.48 Mn |
| Mar 31, 2025 | 10.48 Mn |
| Dec 31, 2024 | -35.68 Mn |
| Dec 31, 2024 | -35.68 Mn |
| Sep 30, 2024 | -34.59 Mn |
| Sep 30, 2024 | -34.59 Mn |
| Jun 30, 2024 | -69.90 Mn |
| Jun 30, 2024 | -69.90 Mn |
| Mar 31, 2024 | 15.24 Mn |
| Mar 31, 2024 | 15.24 Mn |